ICON Enhances Endpoint Adjudication Services for Clinical Trials Using AG Mednet Advanced Technology


Company News Release

ICON plc

 (NASDAQ: ICLR), a global provider of drug development and commercialization solutions and services, announced it has signed an agreement with AG Mednet to use Judi, a comprehensive electronic endpoint adjudication system, to manage workflow and ensure data quality for enhanced endpoint event adjudication services.   Judi, an integrated, cloud-based SaaS tool, provides a level of flexibility that enables the implementation of the most complex endpoint and adverse event processes, delivering fewer queries, higher transparency and increased quality for clients.   ICON is a leader in endpoint adjudication and has already successfully deployed Judi for thousands of events across multiple therapeutic areas including oncology, obesity and diabetes. It has established relationships with more than 400 experts and key opinion leaders around the world, and works with multiple partners and Academic Research Organizations in support of Data Monitoring Committees and event adjudication.   “Judi provides a purpose-built solution for endpoint adjudication that enables efficient database set-up and data extraction, and manages workflow effectively,” said Craig McLendon, Senior Director, Adjudication and Data Monitoring Committees Management, ICON. “Combining ICON’s adjudication experience and expertise with innovative technology from AG Mednet enables us provide a world-class service for even the most demanding endpoint adjudication projects”.   “We developed Judi from the ground up, incorporating a level of flexibility that enables quality and accuracy in reported data from studies. ICON has been an ideal partner in ensuring that both the development and the implementation of Judi meet the technical and clinical needs of investigator sites, CRO reviewers, adjudicators and clinical event committees,” said Abraham Gutman, president and CEO, AG Mednet.   ICON provides customized, efficient, streamlined, high-quality, regulatory compliant solutions for projects of all sizes and all therapeutic areas.    

About ICON plc

ICON plc is a global provider of outsourced drug development and commercialization solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organizations. The company specializes in the strategic development, management and analysis of programs that support clinical development from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 97 locations in 38 countries and has approximately 13,380 employees. Further information is available at 



About AG Mednet

AG Mednet is the leading quality compliance partner for image data submission and collection, as well as endpoint adjudication and adverse event adjudication workflows. The company is a leading proponent of zero-delay clinical trials, and has supported more than 1,000 global clinical trials. Dozens of adjudication protocols are managed by sponsors and CROs using Judi. More than 55,000 registered users across thousands of investigator sites in more than 80 countries use AG Mednet to submit more than 14,000,000 images per month and adjudicate hundreds of events in projects sponsored by each of the world’s top 20 pharmaceutical, biotech and medical device companies. 


Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Related Content
© 2024 MJH Life Sciences

All rights reserved.